In addition, BARD1β has been demonstrated to enhance the sensitivity of CRC cells to poly PARP-1 inhibition, suggesting that it is a promising biomarker for assessing the suitability of homologous recombination targeting with PARPi in the treatment of advanced CRC (43). This evidence concerns the gene PARP1 and colorectal carcinoma.